Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Specializing In
- Bladder Cancer
- Cancer Surgery
- Cystoscopy
- Intravesical Therapy
- Kidney Cancer
Biography
Dr. Jay Shah, MD currently serves as Chief of the Medical Staff for Stanford Health Care. He is a cancer surgeon and associate professor of Urology at the Stanford University School of Medicine. His clinical focus is on bladder cancer, and he is well known for his expertise in robotic surgery. His academic interests center on optimizing outcomes after bladder removal surgery. He is very active in leadership development, team building, and quality improvement work and he lectures nationally and internationally on these topics. He is also certified by the International Coaching Federation as an executive coach.
Dr. Shah graduated from Harvard College, and he completed medical school and urology residency training at Columbia University. During his time at Columbia, Dr. Shah was elected to the Alpha Omega Alpha Medical Honor Society; he was named Physician of the Year by the nursing staff; and he was recognized by the medical students with the Gold Foundation Excellence in Teaching Award. After residency, he completed a three-year fellowship in Urologic Oncology at MD Anderson Cancer Center and then joined the faculty there. During his time at MD Anderson, Dr. Shah launched the bladder cancer robotics program, developed an enhanced recovery program for patients undergoing bladder removal surgery, became double board-certified in Urology and Medical Quality, and was chosen to lead the MDACC Genitourinary Center as Center Medical Director.
In his free time, Dr. Shah enjoys reading, cooking, and exploring the beaches of Northern California with his family and three dogs.
In his free time, Dr. Shah enjoys reading, cooking, surfing, hiking and exploring the beaches of Northern California in his Jeep Wrangler with his family and 2 dogs.
Dr. Shah graduated from Harvard College, and he completed medical school and urology residency training at Columbia University. During his time at Columbia, Dr. Shah was elected to the Alpha Omega Alpha Medical Honor Society; he was named Physician of the Year by the nursing staff; and he was recognized by the medical students with the Gold Foundation Excellence in Teaching Award. After residency, he completed a three-year fellowship in Urologic Oncology at MD Anderson Cancer Center and then joined the faculty there. During his time at MD Anderson, Dr. Shah launched the bladder cancer robotics program, developed an enhanced recovery program for patients undergoing bladder removal surgery, became double board-certified in Urology and Medical Quality, and was chosen to lead the MDACC Genitourinary Center as Center Medical Director.
In his free time, Dr. Shah enjoys reading, cooking, and exploring the beaches of Northern California with his family and three dogs.
In his free time, Dr. Shah enjoys reading, cooking, surfing, hiking and exploring the beaches of Northern California in his Jeep Wrangler with his family and 2 dogs.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification, Medical Quality, American Board of Medical Quality (2015)
- Healthcare Course, Harvard Business School Extension Program, Cambridge, MA, Value Measurement (2015)
- Board Certification: American Board of Urology, Urology (2012)
- Urologic Oncology Fellowship, MD Anderson Cancer Center, Houston, TX (2010)
- Fellowship: MD Anderson Cancer Center Urologic Oncology (2010) TX
- Urology Chief Residency, Columbia University Medical Center, New York, NY (2007)
- Urology Residency, Columbia University Medical Center, New York, NY (2006)
- General Surgery Internship, Columbia University Medical Center, New York, NY (2003)
- Medical Education: Columbia University College of Physicians and Surgeons (2002) NY
- BA in Biological Sciences, Harvard College, Cambridge, MA (1998)
Honors & Awards
- Clinical Effectiveness Leadership Training, Stanford Medicine (2017-2018)
- Clinical Innovator Award, MD Anderson Cancer Center (2015-2017)
- Comparative Effectiveness Research on Cancer, Texas Scholar Award (2012-2014)
- Distinguished Alumnus Award, Columbia University Department of Urology (2019)
- Faculty, Clinical Effectiveness Leadership Training, Stanford Medicine (2018-2020)
- Genitourinary SPORE Career Development Award, MD Anderson Cancer Center (2014-2016)
- Gerald P. Murphy Scholar, Ford Library and Museum (2006)
- Humanism and Excellence in Teaching Award, Columbia Medical School (2006)
- Humanism Honor Society Inductee, Arnold P. Gold Foundation (2006)
- Leadership Academy, American Urological Association (2016-2017)
- Physician of the Year, Columbia University Medical Center (2006)
- Resident of the Year, Columbia University Department of Urology (2006)
- Stanford Leadership Development Program, Stanford Hospital (2017-2018)
- Stanford Medicine Leadership Academy, Stanford School of Medicine (2018-2019)
Administrative Appointments
- Center Medical Director, MDACC Genitourinary Center (2016 - 2016)
- Chief of Staff, Stanford Health Care (2022 - Present)
- Clinic Advisory Council, Stanford Hospital (2019 - Present)
- Co-Quality Improvement Officer, MDCC Department of Urology (2014 - 2016)
- Committee on Professionalism, Stanford Hospital (2020 - Present)
- Director, MDACC Department of Urology Medical Student Education (2010 - 2015)
- Director, MDACC Bladder Cancer Robotics Program (2014 - 2016)
- Genitourinary Cancer Care Program Leader, Stanford Cancer Center (2017 - 2022)
- Member, American Urological Association International Academic Fellowship Committee (2015 - Present)
- Physician Improvement Leader, Stanford University Department of Urology (2017 - 2022)
- Supervisor, MDACC Department of Urology Journal Club (2012 - 2015)
- Value-based Care Champion, Stanford University Department of Urology (2020 - 2022)
- Vice Chief of Staff, Stanford Health Care (2020 - 2022)
Publications
-
Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy
Mitchell, R. E., Desai, M., Shah, J. B., Olsson, C. A., Benson, M. C., & McKiernan, J. M. (2006). Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. JOURNAL OF UROLOGY, 175(5), 1663–67. -
Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: Impact of grade migration in prostate cancer
Mitchell, R. E., Shah, J. B., Desai, M., Mansukhani, M. M., Olsson, C. A., Benson, M. C., & McKiernan, J. M. (2007). Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: Impact of grade migration in prostate cancer. UROLOGY, 70(4), 706–10. -
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design
Mmeje, C. O., Guo, C. C., Shah, J. B., Navai, N., Grossman, H. B., Dinney, C. P., & Kamat, A. M. (2016). Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design. EUROPEAN UROLOGY, 70(5), 778–85. -
Association between Perioperative Blood Transfusions and Clinical Outcomes in Patients Undergoing Bladder Cancer Surgery: A Systematic Review and Meta-Analysis Study.
Cata, J. P., Lasala, J., Pratt, G., Feng, L., & Shah, J. B. (2016). Association between Perioperative Blood Transfusions and Clinical Outcomes in Patients Undergoing Bladder Cancer Surgery: A Systematic Review and Meta-Analysis Study. Journal of Blood Transfusion, 2016, 9876394-? -
PSA updated: Still relevant in the new millennium?
Shah, J. B., Reese, A. C., McKiernan, J. M., & Benson, M. C. (2005). PSA updated: Still relevant in the new millennium? EUROPEAN UROLOGY, 47(4), 427–32. -
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
Zargar, H., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Bivalacqua, T. J., Spiess, P. E., … Kassouf, W. (2018). Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. JOURNAL OF UROLOGY, 199(6), 1453–59. -
Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study
Haddad, A. Q., Hutchinson, R., Wood, E. L., Miranda, G., Gershman, B., Messer, J., … Lotan, Y. (2017). Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. CLINICAL GENITOURINARY CANCER, 15(6), 689-+. -
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study
Daneshmand, S., Patel, S., Lotan, Y., Pohar, K., Trabulsi, E., Woods, M., … Jones, J. S. (2018). Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. JOURNAL OF UROLOGY, 199(5), 1158–86. -
Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy
Kukreja, J. B., Shi, Q., Chang, C. M., Seif, M. A., Sterling, B. M., Chen, T.-Y., … Wang, X. S. (2018). Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. SURGICAL INNOVATION. SAGE PUBLICATIONS INC. -
Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy
Mmeje, C. O., Benson, C. R., Nogueras-Gonzalez, G. M., Jayaratna, I. S., Gao, J., Siefker-Radtke, A. O., … Shah, J. B. (2018). Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU INTERNATIONAL, 122(1), 89–98. -
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
Monteiro, L. L., Witjes, J. A., Agarwal, P. K., Anderson, C. B., Bivalacqua, T. J., Bochner, B. H., … Kassouf, W. (2019). ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. WORLD JOURNAL OF UROLOGY, 37(1), 51–60. -
Neurocognitive deficits in older patients with cancer.
Edwards, B. J., Zhang, X., Sun, M., Holmes, H. M., Ketonen, L., Guha, N., … Champlin, R. E. (2018). Neurocognitive deficits in older patients with cancer. Journal of Geriatric Oncology, 9(5), 482–487. -
Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.
Edwards, B. J., Sun, M., Zhang, X., Holmes, H. M., Song, J., Khalil, P., … Murphy, W. A. (2018). Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 26(5), 1561–1568. -
Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.
Zhang, X., Sun, M., McKoy, J. M., Bhulani, N. N., Valero, V., Barcenas, C. H., … Edwards, B. J. (2018). Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. Journal of Geriatric Oncology, 9(1), 81–83. -
Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja, J. B., Porten, S., Golla, V., Ho, P. L., Noguera-Gonzalez, G., Navai, N., … Shah, J. B. (2018). Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus, 4(5), 720–724. -
Dose dense MVAC prior to radical cystectomy: a real-world experience.
Zargar, H., Shah, J. B., van de Putte, E. E., Potvin, K. R., Zargar-Shoshtari, K., van Rhijn, B. W., … Kassouf, W. (2017). Dose dense MVAC prior to radical cystectomy: a real-world experience. World Journal of Urology, 35(11), 1729–1736. -
Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study.
Haddad, A. Q., Hutchinson, R., Wood, E. L., Miranda, G., Gershman, B., Messer, J., … Lotan, Y. (2017). Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. Clinical Genitourinary Cancer, 15(6), 689–695.e2. -
Advances in surgical management of muscle invasive bladder cancer.
Kukreja, J. B., & Shah, J. B. (2017). Advances in surgical management of muscle invasive bladder cancer. Indian Journal of Urology : IJU : Journal of the Urological Society of India, 33(2), 106–110. -
Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.
Fernández, M. I., Williams, S. B., Willis, D. L., Slack, R. S., Dickstein, R. J., Parikh, S., … Kamat, A. M. (2017). Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 119(5), 684–691. -
Risk of hospitalisation after primary treatment for prostate cancer.
Williams, S. B., Duan, Z., Chamie, K., Hoffman, K. E., Smith, B. D., Hu, J. C., … Giordano, S. H. (2017). Risk of hospitalisation after primary treatment for prostate cancer. BJU International, 120(1), 48–55. -
Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments.
Danna, B. J., Metcalfe, M. J., Wood, E. L., & Shah, J. B. (2016). Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments. Bladder Cancer (Amsterdam, Netherlands), 2(3), 329–340. -
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.
Navai, N., Benedict, W. F., Zhang, G., Abraham, A., Ainslie, N., Shah, J. B., … Dinney, C. P. (2016). Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Annals of Surgical Oncology, 23(12), 4110–4114. -
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.
Kamat, A. M., Agarwal, P., Bivalacqua, T., Chisolm, S., Daneshmand, S., Doroshow, J. H., … Rosenberg, J. E. (2016). Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer (Amsterdam, Netherlands), 2(2), 203–213. -
The Future of Enhanced Recovery for Radical Cystectomy: Current Evidence, Barriers to Adoption, and the Next Steps.
Danna, B. J., Wood, E. L., Baack Kukreja, J. E., & Shah, J. B. (2016). The Future of Enhanced Recovery for Radical Cystectomy: Current Evidence, Barriers to Adoption, and the Next Steps. Urology, 96, 62–68. -
Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
Zargar, H., Zargar-Shoshtari, K., Lotan, Y., Shah, J. B., van Rhijn, B. W., Daneshmand, S., … Black, P. (2016). Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? The Journal of Urology, 195(4 Pt 1), 886–93. -
Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
Zargar-Shoshtari, K., Zargar, H., Dinney, C. P., Ercole, C. E., Sharma, P., Kovac, E., … Spiess, P. E. (2016). Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World Journal of Urology, 34(5), 695–701. -
A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
Zargar-Shoshtari, K., Zargar, H., Lotan, Y., Shah, J. B., van Rhijn, B. W., Daneshmand, S., … Black, P. C. (2016). A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. The Journal of Urology, 195(1), 53–9. -
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.
Davis, J. W., Ward, J. F., Pettaway, C. A., Wang, X., Kuban, D., Frank, S. J., … Kim, J. (2016). Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU International, 118(1), 68–76. -
Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?
Rozanski, A. T., Benson, C. R., McCoy, J. A., Green, C., Grossman, H. B., Svatek, R. S., & Shah, J. B. (2015). Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging? Bladder Cancer (Amsterdam, Netherlands), 1(1), 91–96. -
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., … Black, P. C. (2015). Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. European Urology, 67(2), 241–9. -
Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.
Svatek, R. S., Clinton, T. N., Wilson, C. A., Kamat, A. M., Grossman, H. B., Dinney, C. P., & Shah, J. B. (2014). Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology, 84(5), 1147–51. -
Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman, K. E., Niu, J., Shen, Y., Jiang, J., Davis, J. W., Kim, J., … Smith, B. D. (2014). Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Internal Medicine, 174(9), 1450–9. -
Strategies for optimizing bacillus Calmette-Guérin.
Shah, J. B., & Kamat, A. M. (2013). Strategies for optimizing bacillus Calmette-Guérin. The Urologic Clinics of North America, 40(2), 211–8. -
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.
Lynch, S. P., Shen, Y., Kamat, A., Grossman, H. B., Shah, J. B., Millikan, R. E., … Siefker-Radtke, A. (2013). Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. European Urology, 64(2), 307–13. -
Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs.
Davis, J. W., Shah, J. B., & Achim, M. (2011). Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU International, 108(6 Pt 2), 993–8. -
New strategies in muscle-invasive bladder cancer: on the road to personalized medicine.
Shah, J. B., McConkey, D. J., & Dinney, C. P. (2011). New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 17(9), 2608–12. -
Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Inamoto, T., Shah, J. B., & Kamat, A. M. (2009). Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urologic Oncology, 27(6), 585–91. -
Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy.
Shah, J. B., McKiernan, J. M., Elkin, E. P., Carroll, P. R., & Meng, M. V. (2008). Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. The Journal of Urology, 179(1), 136–40. -
Water under the bridge: 5-year outcomes after percutaneous ablation of obstructing parapelvic renal cysts.
Shah, J. B., Whitman, C., Lee, M., & Gupta, M. (2007). Water under the bridge: 5-year outcomes after percutaneous ablation of obstructing parapelvic renal cysts. Journal of Endourology, 21(10), 1167–70. -
New treatments for superficial bladder cancer.
Shah, J. B., Badalato, G. M., & McKiernan, J. M. (2006). New treatments for superficial bladder cancer. Current Oncology Reports, 8(3), 201–5. -
Does year of radical prostatectomy independently predict outcome in prostate cancer?
Mitchell, R. E., Shah, J. B., Olsson, C. A., Benson, M. C., & McKiernan, J. M. (2006). Does year of radical prostatectomy independently predict outcome in prostate cancer? Urology, 67(2), 368–72. -
Hypogonadism and metabolic syndrome: implications for testosterone therapy.
Makhsida, N., Shah, J., Yan, G., Fisch, H., & Shabsigh, R. (2005). Hypogonadism and metabolic syndrome: implications for testosterone therapy. The Journal of Urology, 174(3), 827–34. -
Novel therapeutics in the treatment of bladder cancer.
Shah, J. B., & McKiernan, J. M. (2004). Novel therapeutics in the treatment of bladder cancer. Current Opinion in Urology, 14(5), 287–93. -
The role of free radicals in chronic rhinosinusitis.
Friedman, A. D., Shah, J. B., Takoudes, T. G., & Haddad, J. (2002). The role of free radicals in chronic rhinosinusitis. Archives of Otolaryngology--Head & Neck Surgery, 128(9), 1055–7. -
Reducing opioid utilization after urologic oncology surgery.
Stevenson, K., Kee, J., Van Zyl, E., Dugala, A., & Shah, J. B. (2018). Reducing opioid utilization after urologic oncology surgery. JOURNAL OF CLINICAL ONCOLOGY, 36(30). -
IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY
Greenberg, D., Kee, J., Stevenson, K., Van Zyl, E., Dugala, A., Prado, K., … Shah, J. (2019). IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY. JOURNAL OF UROLOGY, 201(4), E1196–E1197. -
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
Black, A. J., Zargar, H., Zargar-Shoshtari, K., Fairey, A. S., Mertens, L. S., Dinney, C. P., … Black, P. C. (2019). The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology. -
Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.
Narayan, V. M., Seif, M. A., Lim, A. H., Li, R., Matulay, J. T., Kukreja, J. B., … Navai, N. (2020). Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urologic Oncology. -
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.
D'Andrea, D., Black, P. C., Zargar, H., Zargar-Shoshtari, K., Zehetmayer, S., Fairey, A. S., … Shariat, S. F. (2020). Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urologic Oncology. -
Implementation of a Reduced Opioid Utilization Protocol for Radical Cystectomy
Greenberg, D. R., Kee, J. R., Stevenson, K., Van Zyl, E., Dugala, A., Prado, K., … Shah, J. B. (2020). Implementation of a Reduced Opioid Utilization Protocol for Radical Cystectomy. BLADDER CANCER, 6(1), 33–42. -
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.
Bhambhvani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., … Shah, J. B. (2020). Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer. Urologic Oncology. -
The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course
Greenberg, D. R., Conti, S. L., & Shah, J. B. (2020). The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course. UROLOGY PRACTICE, 7(4), 322–27. -
Clinical -Bladder cancer Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
D'Andrea, D., Black, P. C., Zargar, H., Zargar-Shoshtari, K., Zehetmayer, S., Fairey, A. S., … Shariat, S. F. (2020). Clinical -Bladder cancer Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(7). -
NEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY IN CT2 BLADDER CANCER: A MULTICENTER STUDY
Giordano, A., Black, P., Fairey, A., Cookson, M., Yu, E., Kassouf, W., … Gontero, P. (2020). NEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY IN CT2 BLADDER CANCER: A MULTICENTER STUDY. ANTICANCER RESEARCH, 40(8), 4636–37. -
POST-OPERATIVE OPIOID FREE URETEROSCOPY: A PROTOCOL PILOT STUDY
Kasman, A., Schmidt, B., Spradling, K., Chow, C., Wu, M., Hunt, R., … Conti, S. (2020). POST-OPERATIVE OPIOID FREE URETEROSCOPY: A PROTOCOL PILOT STUDY. JOURNAL OF UROLOGY, 203, E162. -
Critical Appraisal of Quality Improvement Publications in the Urological Literature
Greenberg, D. R., Sohlberg, E. M., Shkolyar, E., & Shah, J. B. (2020). Critical Appraisal of Quality Improvement Publications in the Urological Literature. UROLOGY PRACTICE, 7(5), 413–17. -
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
Soria, F., Black, P. C., Fairey, A. S., Cookson, M. S., Yu, E. Y., Kassouf, W., … Gontero, P. (2020). Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU International. -
Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?
Schmidt, B., Bhambhvani, H. P., Greenberg, D. R., Prado, K., Shafer, S., Thong, A., … Shah, J. B. (2020). Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter? Urologic Oncology. -
Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers.
Kukreja, J. B., Seif, M. A., Mery, M. W., Incalcaterra, J. R., Kamat, A. M., Dinney, C. P., … Navai, N. (2020). Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urologic Oncology. -
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.
D'Andrea, D., Black, P. C., Zargar, H., Zargar-Shoshtari, K., Soria, F., Fairey, A. S., … Shariat, S. F. (2021). Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology. -
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
D'Andrea, D., Black, P. C., Zargar, H., Dinney, C. P., Soria, F., Cookson, M. S., … Moschini, M. (2021). Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer. The Journal of Urology, 101097JU0000000000002190. -
Postoperative opioid-free ureteroscopy discharge: A quality initiative pilot protocol.
Kasman, A. M., Schmidt, B., Spradling, K., Chow, C., Hunt, R., Wu, M., … Conti, S. L. (2021). Postoperative opioid-free ureteroscopy discharge: A quality initiative pilot protocol. Current Urology, 15(3), 176–180. -
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Einerhand, S. M., Black, A. J., Zargar, H., Fairey, A. S., Dinney, C. P., Mir, M. C., … Mertens, L. S. (2022). Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology. -
Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa).
Bochner, B. H., Feifer, A., Sperling, D., Mashni, J. W., Bajorin, D. F., Shah, J. B., … Lotan, Y. (2014). Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa
Jaeger, W., Horiguchi, Y., Shah, J., Hayashi, T., Awrey, S., Gust, K. M., … Black, P. C. (2013). Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa. JOURNAL OF UROLOGY, 190(4), 1404–1409. -
Demographic analysis of randomized controlled trials in bladder cancer
Bachir, B. G., Shariat, S. F., Zlotta, A., Svatek, R., Black, P. C., Shah, J. B., & Kassouf, W. (2013). Demographic analysis of randomized controlled trials in bladder cancer. BJU INTERNATIONAL, 111(3), 419–426. -
A survey of US medical education in otolaryngology
Haddad, J., Shah, J., & Takoudes, T. G. (2003). A survey of US medical education in otolaryngology. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 129(11), 1166–1169. -
Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review.
Antonelli, L., Sebro, K., Lahmar, A., Black, P. C., Ghodoussipour, S., Hamilton-Reeves, J. M., … Fankhauser, C. D. (2023). Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review. European Urology Focus. -
Multiphase preclinical assessment of a novel device to locate unintentionally retained surgical sharps: a proof-of-concept study.
Kang, H. S., Khoraki, J., Gie, J., Duval, D., Haynes, S., Siev, M., … Weprin, S. (2023). Multiphase preclinical assessment of a novel device to locate unintentionally retained surgical sharps: a proof-of-concept study. Patient Safety in Surgery, 17(1), 10. -
A Leak in the System: Addressing the Environmental Impact of Urologic Care.
Kornberg, Z., Wu, J., Wilmot, H., Duffina, T., & Shah, J. B. (2023). A Leak in the System: Addressing the Environmental Impact of Urologic Care. European Urology. -
Critical Appraisal of Quality Improvement Publications in the Urological Literature.
Greenberg, D. R., Sohlberg, E. M., Shkolyar, E., & Shah, J. B. (2020). Critical Appraisal of Quality Improvement Publications in the Urological Literature. Urology Practice, 7(5), 413–418. -
The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course.
Greenberg, D. R., Conti, S. L., & Shah, J. B. (2020). The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course. Urology Practice, 7(4), 322–328. -
Reply by Authors.
Greenberg, D. R., Conti, S. L., & Shah, J. B. (2020). Reply by Authors. Urology Practice, 7(4), 328. -
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.
Ho, M. D., Black, A. J., Zargar, H., Fairey, A. S., Mertens, L. S., Dinney, C. P., … Black, P. C. (2023). The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy. Canadian Urological Association Journal = Journal De l'Association Des Urologues Du Canada, 17(10), 301–309.
Practice Locations
Urologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Urologic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Urologic Cancer Program in San Jose San Jose, CA
San Jose, CA
Urologic Cancer Program in San Jose
2589 Samaritan Drive
San Jose , CA 95124
Make An Appointment More Clinic Information » Getting Here »Cancer Center in South Bay San Jose, CA
San Jose, CA
Cancer Center in South Bay
2589 Samaritan Drive
San Jose , CA 95124
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(97 reviews)
Very thorough physician, looking for the best outcome for his patients.
Dr Shah provides excellent care
He is thoughtful, kind, and more than competent. He keeps me in the loop with explanations I can understand. He makes me feel as if I am part of the team. I know I can be a difficult patient at times and he just gently moves right around those moments and helps me understand another possibility. It's not a common thing to have confidence in your doctor these days, but with Dr Shah I am more than confident putting my life in his hands.
Forthright, competent, communicative.
The whole team was incredible, from check-in, to the MA who roomed me, to Stacy his nurse who checked in on me and made sure I was okay for my procedure. Dr Shah was very kind and reassuring. My appointment went smoothly and efficiently, and still I felt extremely cared for.
Very kind voice and attitude. Felt very secure about the road ahead. For someone as myself who has not had any real tough medical situation in my whole life I feel confident with Dr. Shah and the team. Thank you.
outstanding " Niceness"
Easy to confer with and pleasing personality
I have no word....truly amazing and caring
Very professional and helpful. I Look forward to meeting in person.
Very good communication and attitude
Someone I would like to be friends with
My conversation with Dr. Shah was extremely thorough and reassuring. I’m much better informed about my future program. Plus he is, dare I say, quite charming
Have recommended already to a friend with Prostate cancer
DR. JAY SHAH IS TOP NOTCH!!
Great doctor, great staff
I have a lot of confidence in Dr. j Shah and feel he has my best interests
in mind when he gives me an opinion.
Dr.Shah is the best doctor in the world!!!
He was friendly, attentive and clear in his explanations. he patiently answered our questions. My wife was on the call also. It was important to find out that he has a close working relationship with my urologist, Dr. Craig Stauffer at Montage Medical Health in Monterey. Dr. Shah provided the second opinion. It was reassuring that he agreed with the diagnosis and the treatment plan proposed by Dr. Stauffer.
Service was exceptional!
Professional empathetic
Dr. Shah and his staff are excellent and have great customer service skills. They are very humbled to this situation as it is hard and confusing with all the terminology. Thanks again for all the support. It was the first visit and both my Dad and I feel good to know we have a great team behind all this. Thank you!
Dr Shah is an excellent doctor and I am very thankful for him.
Jay’s the best
Very professional
A very good experience. Everyone was very helpful and so nice.
They’ were nice an they took good care of me
Kindly, friendly, on time.
Over all excellent. Dr. Shaw is a remarkable Dr. I can't say enough good about all the options he covered and gave me GREAT hope for the future. I feel truly blessed to have had the meeting with him.
Dr ShAh is a excellent doctor and is a huge asset for stanford.
Dr Shah was very caring, considerate and professional. I felt like he was very present with me and not rushed. I felt listened to, respected and understood by him. I very much appreciated his time with me and I greatly value his expertise and opinions. I'm also grateful for the time and consideration of his support staff. Wonderful interactions all the way around!
Many thanks :)
Explanations clear. Confident in his knowledge and care.
Very knowledgeable and attentive to the details.
I liked him
Honest and straightforward
I think Dr. Shah was clearly interested about my case and wanted to help me the best way he can.
My care team for the last Three and one half years took very good care of me. I will miss them all.
Dr Shah was very informative about my treatment! Thank you
He’s a pro and he’s personable.
Solid. Delivering care based on the patient.
I am very happy Dr Shaw takes care very good.
So friendly, fast and very comfortable.
My favorite Doctor in the world
I'm always treated well by all of the Stanford Staff
Excellent physician!
He was very polite courteous and empathetic with my situation. I felt very comfortable in speaking with him candidly about my condition. He definitely exceeded my expectations for this visit I would recommend him and Stanford medicine to anybody who may need your services great job
Dr Shaw was well prepared, competent and approachable. He gave me confidence that we would make the right decision and execute it well.
Dr Shah listened. What a help that is!
He made sure we understood what to expect in the next few months.
We very much appreciate his sense of humor.
Extremely excited and grateful to have him on our care team.
Dr shah is great!
great service, kindly, friendly, fast and on time.
Dr Shah is the best .
Outstanding dr and staff
I would recommend this care provider to anyone who needed cancer treatment.
Dr. Shah answered all of my questions and concerns in not only a professional manner but also that his bed side manner made me feel
that he truly cared about my well-being and about my quality of life concerns.
Everything was excellent during the video visit with Dr.Shah
He is a very nice kind doctor he speak Spanish and English Making sure my mom and me got all the details and all the Answers.
It was an honor And pleasure to meet doctor Jay S.
He and his staff were very clear and concise with a course of treatment moving forward
very professional
He clearly explained the upcoming procedure and I felt he genuinely cared about my mother’s well being.
Even after meeting Dr. Shah for the first time on a video conference call,
I felt that he took a personal interest in my welfare and that I have complete confidence that he will take care of me.
He was very interested in hearing about me and my involvements in the community and volunteer work. Very caring and concerned. He was very easy to communicate with. a very complete Dr. visit.
Dr. Shah's Fellow talked with me first, shortly after I came online. He was excellent, gave me an insightful and clear view of my situation, and answered all of my questions beyond my satisfaction. I didn't think anybody could top that, but when Dr. Shah came on, he added even more insight and clarity to my understanding. Nurse Stacy was similarly clear and thorough in explaining specifics about my surgery and answering my questions. It's obvious that this is an impeccable and coordinated team who have all the factors of my situation in view.
Very professional demeanor and explained things in a way that help put our mind at ease over the future of my treatment.
Best beside manner! Even under these circumstances we managed to laugh and joke. He put me completely at ease with the process and the prognosis. I just told my daughter this was the best doctor visit I’ve ever had, which seems odd, considering it’s the most serious diagnosis I’ve ever had.
Best Dr. ever.
Great interview! Dr. Jay was very personable, knowledgeable, and easy to communicate with.
Dr. Shah was very thorough and understanding.
Dr. Shah was personable and had me laughing after an incident happened on my end.
I would recommend Dr. Shah
Dr Shaw explained everything to me in the most methodical, empathetic, and patiently too! My visit with Dr Shah changed my entire outlook on my diagnosis, and I am grateful to Dr Shah and Stanford to offer me this process and option.
Dr. Shah impressed me as knowledgeable, caring and smart physician who communicates very well. With patients
He gave me a lot of info and answered all my questions
My mother and I had an excellent visit with Dr. Shah. I appreciated his patience in explaining the best course of action that he and his team recommended for my mother's bladder cancer. My mother felt confident after the visit that she was in good hands!
Dr Jay Shad friendly and make my Dad fell more comfortable about his Cancer .
I am very grateful to the Doctor SHAH, JAY BAKUL MD, and his team for their attentiveness, kindness and assistance to the patient.
This is a great experience, they're efficient, friendly, & caring. So far, best time ever seen.
Dr. Shah is wonderful. Made me feel like a friend. Bedside manner is perfect, friendly and professional.
Superb.
Dr. Schmidt & Dr. Shah were clear and thorough with our fist consultation visit. Very pleasant visit overall.
I really like Dr. Shah.
Dr. Shah was very informative & patient in answering all my questions.
My doctor, Doctor Shah Jay is the best doctor, the most professional, and kind. He saved my life!!!!
It doesn't get any better
Dr. Jay Shah was very caring & gave us valuable information. He was terrific.
Thanks Dr. Shah.
Always good experience.
Shah is a very easy to talk to dr. and the nurse helper made it fun by taking my mind off of the test I underwent.
Dr. Shah was one of the kindest Doctor"s that I have ever met. He has a very good bedside manner.
Over the time I have been seeing him, Dr. Shah has improved greatly in terms of all of the above & I have confidence in him.
Dr. Shah, Jay Bajul is the best doctor in the world. He is very professional, kind, polite, he is the best surgeon, Dr. Shah is saving my life, I trust him a lot (please, let him know about it).
Doctor didn't spend much time with me. Seemed to be very busy. I'd like a more personal attitude.
The doctor spent more time with me than during past visits & I rate him higher--very much improved.
My Doctor Shah Jay Bakul is the next wonder in the world!!!
I felt like the appointment was rushed. I didn't have many questions & he answered the ones I had. The main problem was he mentioned types of future treatments for my cancer & at the end casually mentioned the organ might have to be surgically removed if treatment wasn't effective. This was a big deal to me, but it didn't seem to be to him & I didn't feel like he was concerned. I think he should have followed through better with this--it was new information for us & we were kind of thrown--didn't know what questions to ask.
Both Dr. Shah & the PA (sorry I forgot her name) were OFF the charts in terms of approach, information, efficiency & advice.
Doctor Jay Shah is the best surgeon in the world!!!
Appreciated the doctor speaking directly with my dad. He was straightforward and considerate. We feel very confident in his care.
Very good!
Dr. Shah and Melda area a great team. A class act, I felt so much better about myself.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records